Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant/persister cells that survive in the presence of...
| Main Authors: | , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
MDPI AG
2020-12-01
|
| 丛编: | Cells |
| 主题: | |
| 在线阅读: | https://www.mdpi.com/2073-4409/9/12/2601 |
| _version_ | 1827700787014270976 |
|---|---|
| author | Mirna Swayden Houssein Chhouri Youssef Anouar Luca Grumolato |
| author_facet | Mirna Swayden Houssein Chhouri Youssef Anouar Luca Grumolato |
| author_sort | Mirna Swayden |
| collection | DOAJ |
| description | The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant/persister cells that survive in the presence of the treatment. Different processes contribute to the emergence of these cells, including pathway rebound through the release of negative feedback loops, transcriptional rewiring mediated by chromatin remodeling and autocrine/paracrine communication among tumor cells and within the tumor microenvironment. In this review, we discuss the non-genetic mechanisms that eventually result in cancer resistance to targeted therapies, with a special focus on those involving changes in gene expression. |
| first_indexed | 2024-03-10T14:19:50Z |
| format | Article |
| id | doaj.art-d3074e727c1549298ec38ff7692218a3 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T14:19:50Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-d3074e727c1549298ec38ff7692218a32023-11-20T23:32:36ZengMDPI AGCells2073-44092020-12-01912260110.3390/cells9122601Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted TherapyMirna Swayden0Houssein Chhouri1Youssef Anouar2Luca Grumolato3Laboratoire Différenciation et Communication Neuronale et Neuroendocrine, UNIROUEN, INSERM, Normandie Université, 76183 Rouen, FranceLaboratoire Différenciation et Communication Neuronale et Neuroendocrine, UNIROUEN, INSERM, Normandie Université, 76183 Rouen, FranceLaboratoire Différenciation et Communication Neuronale et Neuroendocrine, UNIROUEN, INSERM, Normandie Université, 76183 Rouen, FranceLaboratoire Différenciation et Communication Neuronale et Neuroendocrine, UNIROUEN, INSERM, Normandie Université, 76183 Rouen, FranceThe capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant/persister cells that survive in the presence of the treatment. Different processes contribute to the emergence of these cells, including pathway rebound through the release of negative feedback loops, transcriptional rewiring mediated by chromatin remodeling and autocrine/paracrine communication among tumor cells and within the tumor microenvironment. In this review, we discuss the non-genetic mechanisms that eventually result in cancer resistance to targeted therapies, with a special focus on those involving changes in gene expression.https://www.mdpi.com/2073-4409/9/12/2601targeted therapydrug resistancetolerant and persister cellsintratumor heterogeneitycell signalingmelanoma |
| spellingShingle | Mirna Swayden Houssein Chhouri Youssef Anouar Luca Grumolato Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy Cells targeted therapy drug resistance tolerant and persister cells intratumor heterogeneity cell signaling melanoma |
| title | Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy |
| title_full | Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy |
| title_fullStr | Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy |
| title_full_unstemmed | Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy |
| title_short | Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy |
| title_sort | tolerant persister cancer cells and the path to resistance to targeted therapy |
| topic | targeted therapy drug resistance tolerant and persister cells intratumor heterogeneity cell signaling melanoma |
| url | https://www.mdpi.com/2073-4409/9/12/2601 |
| work_keys_str_mv | AT mirnaswayden tolerantpersistercancercellsandthepathtoresistancetotargetedtherapy AT housseinchhouri tolerantpersistercancercellsandthepathtoresistancetotargetedtherapy AT youssefanouar tolerantpersistercancercellsandthepathtoresistancetotargetedtherapy AT lucagrumolato tolerantpersistercancercellsandthepathtoresistancetotargetedtherapy |